|Bid||13.80 x 2200|
|Ask||16.00 x 1100|
|Day's Range||14.47 - 15.08|
|52 Week Range||10.10 - 20.99|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 04, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.20|
Ladies and gentlemen, thank you for standing by and welcome to the TransMedics Q3 2020 Earnings Call. Earlier today TransMedics released financials results for the quarter ended September 30, 2020. Before we begin, I'd like to remind you that management will make statements during this call, that include forward-looking statements, within the meaning of federal securities laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.
TransMedics (TMDX) delivered earnings and revenue surprises of 42.42% and 19.58%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today reported financial results for the quarter ended September 30, 2020.